Outcomes in COVID-19 metformin studies
Outcomes in metformin studies. Studies to date are mostly with diabetic patients.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Reis (DB RCT) -15% 1.15 [0.73-1.83] hosp./ER 32/217 27/206 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment -15% 1.15 [0.73-1.83] 32/217 27/206 -15% improvement Luo 75% 0.25 [0.07-0.84] death 3/104 22/179 Improvement, RR [CI] Treatment Control Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Chen 33% 0.67 [0.20-1.78] death 4/43 15/77 Bramante 7% 0.93 [0.81-1.06] death 394/2,333 791/3,923 Crouse 61% 0.39 [0.16-0.87] death 8/76 34/144 Wander 15% 0.85 [0.80-0.90] death Tau​2 ​ = 0.01; I​2 ​ = 56.6% PrEP 17% 0.83 [0.71-0.97] 410/2,565 875/4,372 17% improvement All studies 15% 0.85 [0.73-0.99] 442/2,782 902/4,578 15% improvement 7 metformin COVID-19 studies c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.01; I​2 ​ = 53.7%; Z = 2.13 Effect extraction pre-specified Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Luo 75% 0.25 [0.07-0.84] 3/104 22/179 Improvement, RR [CI] Treatment Control Wang 58% 0.42 [0.01-1.98] 1/9 13/49 Chen 33% 0.67 [0.20-1.78] 4/43 15/77 Bramante 7% 0.93 [0.81-1.06] 394/2,333 791/3,923 Crouse 61% 0.39 [0.16-0.87] 8/76 34/144 Wander 15% 0.85 [0.80-0.90] Tau​2 ​ = 0.01; I​2 ​ = 56.6% PrEP 17% 0.83 [0.71-0.97] 410/2,565 875/4,372 17% improvement All studies 17% 0.83 [0.71-0.97] 410/2,565 875/4,372 17% improvement 6 metformin COVID-19 mortality results c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.01; I​2 ​ = 56.6%; Z = 2.38 Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wander 2% 0.98 [0.92-1.06] Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% PrEP 2% 0.98 [0.92-1.06] 2% improvement All studies 2% 0.98 [0.92-1.05] 2% improvement 1 metformin COVID-19 ICU result c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.56 Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wander 3% 0.97 [0.94-1.01] hosp. Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% PrEP 3% 0.97 [0.94-1.01] 3% improvement All studies 3% 0.97 [0.94-1.00] 3% improvement 1 metformin COVID-19 hospitalization result c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 2.14 Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Reis (DB RCT) -15% 1.15 [0.73-1.83] hosp./ER 32/217 27/206 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment -15% 1.15 [0.73-1.83] 32/217 27/206 -15% improvement Luo 75% 0.25 [0.07-0.84] death 3/104 22/179 Improvement, RR [CI] Treatment Control Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Chen 33% 0.67 [0.20-1.78] death 4/43 15/77 Bramante 7% 0.93 [0.81-1.06] death 394/2,333 791/3,923 Crouse 61% 0.39 [0.16-0.87] death 8/76 34/144 Wander 15% 0.85 [0.80-0.90] death Tau​2 ​ = 0.01; I​2 ​ = 56.6% PrEP 17% 0.83 [0.71-0.97] 410/2,565 875/4,372 17% improvement All studies 15% 0.85 [0.73-0.99] 442/2,782 902/4,578 15% improvement 7 metformin COVID-19 serious outcomes c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.01; I​2 ​ = 53.7%; Z = 2.13 Effect extraction pre-specified Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Reis (DB RCT) 4% 0.96 [0.85-1.10] viral+ 217 (n) 206 (n) Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment 4% 0.96 [0.85-1.10] 0/217 0/206 4% improvement All studies 4% 0.96 [0.84-1.09] 0/217 0/206 4% improvement 1 metformin COVID-19 viral clearance result c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.59 Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Reis (DB RCT) -15% 1.15 [0.73-1.83] hosp./ER 32/217 27/206 Improvement, RR [CI] Treatment Control Tau​2 ​ = 0.00; I​2 ​ = 0.0% Early treatment -15% 1.15 [0.73-1.83] 32/217 27/206 -15% improvement All studies -15% 1.15 [0.71-1.85] 32/217 27/206 -15% improvement 1 metformin COVID-19 Randomized Controlled Trials c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.00; I​2 ​ = 0.0%; Z = 0.58 Effect extraction pre-specified Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Luo 75% 0.25 [0.07-0.84] death 3/104 22/179 Improvement, RR [CI] Treatment Control Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Chen 33% 0.67 [0.20-1.78] death 4/43 15/77 Bramante 7% 0.93 [0.81-1.06] death 394/2,333 791/3,923 Crouse 61% 0.39 [0.16-0.87] death 8/76 34/144 Wander 15% 0.85 [0.80-0.90] death Tau​2 ​ = 0.01; I​2 ​ = 56.6% PrEP 17% 0.83 [0.71-0.97] 410/2,565 875/4,372 17% improvement All studies 17% 0.83 [0.71-0.97] 410/2,565 875/4,372 17% improvement 6 metformin COVID-19 peer reviewed trials c19early.com/mf Oct 16, 2021 Tau​2 ​ = 0.01; I​2 ​ = 56.6%; Z = 2.38 Effect extraction pre-specified Favors metformin Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Reis (DB RCT) -15% 1.15 [0.73-1.83] hosp./ER 32/217 27/206 Improvement, RR [CI] Treatment Control Reis (DB RCT) -18% 1.18 [0.74-1.89] hosp./ER 217 (n) 206 (n) Reis (DB RCT) 4% 0.96 [0.85-1.10] viral+ 217 (n) 206 (n) Luo 75% 0.25 [0.07-0.84] death 3/104 22/179 Wang 58% 0.42 [0.01-1.98] death 1/9 13/49 Chen 33% 0.67 [0.20-1.78] death 4/43 15/77 Bramante 7% 0.93 [0.81-1.06] death 394/2,333 791/3,923 Bramante 24% 0.76 [0.60-0.96] death 1,129 (n) 2,173 (n) Bramante 4% 0.96 [0.82-1.14] death 1,204 (n) 1,750 (n) Crouse 61% 0.39 [0.16-0.87] death 8/76 34/144 Wander 15% 0.85 [0.80-0.90] death Wander 2% 0.98 [0.92-1.06] ICU Wander 3% 0.97 [0.94-1.01] hosp. metformin COVID-19 outcomes c19early.com/mf Oct 16, 2021 Favors metformin Favors control
Please send us corrections, updates, or comments.
Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC .
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
